Ares Financial Consulting’s PTC Therapeutics PTCT Stock Holding History

Ares Financial Consulting’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.77K	Buy	+34	New	+$2.46K	﹤0.01%	836

Other funds holding PTCT

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Ares Financial Consulting's PTCT Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 34 shares worth $2.77K. The stake represents ﹤0.01% of the portfolio and ranks #836 among its holdings.

137 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Ares Financial Consulting held 34 shares of PTC Therapeutics worth $2.77K as of Q2 2026.
PTC Therapeutics was a new Ares Financial Consulting position in Q2 2026.
PTC Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #836 holding.
137 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.